Home » Stocks » RespireRx Pharmaceuticals

RespireRx Pharmaceuticals, Inc. (RSPI)

Stock Price: $0.0054 USD -0.0020 (-27.03%)
Updated Oct 21, 2020 9:45 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 585,171
Revenue (ttm) n/a
Net Income (ttm) -2.86M
Shares Out 108.37M
EPS (ttm) -0.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $0.0054
Previous Close $0.0074
Change ($) -0.0020
Change (%) -27.03%
Day's Open 0.0045
Day's Range 0.0040 - 0.0054
Day's Volume 9,045,644
52-Week Range 0.0033 - 0.4

More Stats

Market Cap 585,171
Enterprise Value 1.94M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 108.37M
Float 63.20M
EPS (basic) -0.43
EPS (diluted) -0.11
FCF / Share 0.00
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1,261
Short Ratio 1.45
Short % of Float 0.00%
Beta 0.44
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income -1.98M
Net Income -2.86M
Free Cash Flow -327,915
Net Cash -1.35M
Net Cash / Share -0.01
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -1,050.34%
ROE n/a
ROIC 38.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$97.50*
Low
97.5
Current: $0.0054
High
97.5
Target: 97.50
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue----0.090.06-0.053.1110.47
Revenue Growth----40.94%---98.45%-70.26%-
Gross Profit----0.090.06-0.053.1110.47
Operating Income-1.74-2.18-4.25-8.47-5.24-4.35-1.14-7.34-2.252.18
Net Income-2.12-2.59-4.29-9.23-5.96-2.71-1.20-7.57-2.261.63
Shares Outstanding3.913.352.421.861.180.590.440.330.250.23
Earnings Per Share-0.54-0.77-1.77-4.95-5.05-22.73-3.25-12.99-9.746.49
Operating Cash Flow-0.49-0.43-0.70-1.33-1.30-0.89-0.18-1.86-1.941.34
Capital Expenditures------0.02--0.040.01
Free Cash Flow-0.49-0.43-0.70-1.33-1.30-0.90-0.18-1.86-1.891.35
Cash & Equivalents0.020.030.080.090.050.160.010.151.663.19
Total Debt1.631.251.151.290.860.580.600.47--
Net Cash / Debt-1.62-1.22-1.06-1.20-0.81-0.41-0.58-0.311.663.19
Assets0.050.120.190.230.150.400.050.201.823.57
Liabilities7.495.864.555.733.012.604.243.191.141.16
Book Value-7.44-5.73-4.36-5.49-2.86-2.20-4.19-2.990.682.40
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name RespireRx Pharmaceuticals, Inc.
Country United States
Employees 2
CEO Timothy Jones

Stock Information

Ticker Symbol RSPI
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: RSPI

Description

RespireRx Pharmaceuticals engages in the discovery and development of pharmaceuticals for the treatment of respiratory disorders. It has two drug platforms comprising ampakines, which are small molecule compounds to enhance the excitatory actions of the neurotransmitter glutamate at the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor complex; and cannabinoids, primarily dronabinol, a synthetic derivative for use in refractory chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS. The company's lead ampakine, CX1739, which is in Phase II clinical studies for drug-induced respiratory depression (RD), as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven respiratory disorders, neurobehavioral disorders, spinal cord injury, neurological diseases, and orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was founded in 1987 and is headquartered in Glen Rock, New Jersey.